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Abstract
Background: Glycated albumin (GA) is an Amadori product used as a marker of hyperglycemia. In this study, we
investigated the effect of GA on insulin secretion from pancreatic b cells.
Methods: Islets were collected from male Wistar rats by collagenase digestion. Insulin secretion in the presence of
non-glycated human albumin (HA) and GA was measured under three different glucose concentrations, 3 mM (G3),
7 mM (G7), and 15 mM (G15), with various stimulators. Insulin secretion was measured with antagonists of
inducible nitric oxide synthetase (iNOS), and the expression of iNOS-mRNA was investigated by real-time PCR.
Results: Insulin secretion in the presence of HA and GA was 20.9 ± 3.9 and 21.6 ± 5.5 μU/3 islets/h for G3 (P =
0.920), and 154 ± 9.3 and 126.1 ± 7.3 μU/3 islets/h (P = 0.046), for G15, respectively. High extracellular potassium
and 10 mM tolbutamide abrogated the inhibition of insulin secretion by GA. Glyceraldehyde, dihydroxyacetone,
methylpyruvate, GLP-1, and forskolin, an activator of adenylate cyclase, did not abrogate the inhibition. Real-time
PCR showed that GA did not induce iNOS-mRNA expression. Furthermore, an inhibitor of nitric oxide synthetase,
aminoguanidine, and NG-nitro-L-arginine methyl ester did not abrogate the inhibition of insulin secretion.
Conclusion: GA suppresses glucose-induced insulin secretion from rat pancreatic b-cells through impairment of
intracellular glucose metabolism.
Background
It has been suggested that glycated albumin (GA) is
associated with the risk of complications in diabetic
patients, and is used as a marker of hyperglycemia [1].
GA is an Amadori product formed non-enzymatically
through the condensation reaction of glucose with reac-
tive proteins under conditions of hyperglycemia [2,3].
Amadori products undergo further irreversible reactions
to yield advanced glycation end-products (AGEs) [4,5].
Thus, Amadori products are formed through a reversi-
ble process that depends on the level of glycemia,
whereas AGEs are produced irreversibly and are strong
inducers of inflammation [6].
Previous studies have shown that GA itself has biolo-
gical effects. Cassese et al. reported that GA induced
insulin resistance in skeletal muscle cells by activating
protein kinase Ca and Src [7]. Other studies have
reported that GA induces the expression of proinflam-
matory molecules such as monocyte chemoattractant
peptide (MCP-1) and interleukin-6 [8], and genes asso-
ciated with fibrosis and neovascularization [9].
In general, Amadori products/AGEs trigger signaling
cascades that produce oxygen free radicals, thus expos-
ing cells to oxidative stress [10,11]. Although one pre-
vious study has indicated that glucose-derived AGEs
inhibit insulin secretion from pancreatic b cells by
increasing the transcription of inducible nitric oxide
synthetase (iNOS) and nitric oxide [12], no investiga-
tions have addressed the effect of GA on insulin secre-
tion from pancreatic b-cells. AGEs bind to a specific cell
surface receptor, the receptor of AGE (RAGE), and
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whether GA binds to RAGE [14], the downstream
mechanism of action of GA still remains unclear. In the
present study, we investigated the effect of GA on insu-
lin secretion from pancreatic b cells and found that GA
inhibits KATP-channel-dependent insulin secretion.
Methods
The present study was approved by the ethics commit-
tee of the Laboratory Animal Research Center at Dok-
kyo Medical University.
Agents
GA, human non-glycated albumin (HA), a-ketoisoca-
pronic acid (a-KIC), and 1,3-dihydroxyacetone dimer
(DHA) were purchased from Sigma-Aldrich (St. Louis,
MO), collagenase, D-glyceraldehyde (glyceraldehyde),
and methylpyruvate from Wako Pure Chemical Indus-
tries Ltd. (Osaka, Japan), Ficoll 400 from Pharmacia
Fine Chemicals (Uppsala, Sweden), Conray 400 (sodium
iotalamate) from Daiichi Pharmaceutical (Tokyo, Japan),
Dulbecco’s modified Eagle medium (DMEM) from Nis-
sui Pharmaceutical Company Ltd. (Tokyo, Japan), gluca-
gon-like peptide-1 (GLP-1) from Peptide Institute
(Osaka, Japan), forskolin and aminoguanidine (AG) from
S i g m aC h e m i c a lC o .( S t .L o u i s ,M O ) ,N G - n i t r o - L - a r g i -
nine methyl ester (L-NAME) from Dojindo Molecular
Technologies, Inc. (Kumamoto, Japan), and disperse
from Godo-Shusei Co. (Chiba, Japan). Anti-human GA
neutralizing antibody, A717, was purchased from Exocell
(Philadelphia, PA).
Animals and procedures
Male Wistar rats, 8-12 weeks after birth, were obtained
from Japan SLC, Inc. (Shizuoka, Japan) and housed under
semi-SPF conditions. The rats were anesthetized by intra-
peritoneal injection of pentobarbital sodium at 50 mg/kg
body weight, and their pancreatic islets were removed
and subjected to collagenase digestion [15]. The islets
were then separated by Ficoll-Conray gradient centrifu-
gation [16], and individually isolated by stereoscopic
microarray in DMEM containing 2% heat-inactivated
fetal calf serum (FCS).
Insulin release from pancreatic islets
The pancreatic islets were cultured overnight at 37°C in
RMPI containing 10% FCS and 5.5 mM glucose, and
preincubated for 90 min in HEPES-buffered solution
containing 5.5 mM glucose at 37°C in 5% CO2-95% O2.
T h r e ei s l e t sw e r et h e np i c k e du pa n di n c u b a t e df o r
60 min at 37°C in 1 mL of bicarbonate buffer (pH 7.4)
under three different glucose concentrations, 54 mg/dL
(3 mM: G3), 126 mg/dL (7 mM: G7), and 170 mg/dL
(15 mM: G15), with various agents.
According to the manufacturer, GA was produced
using a method described elsewhere [17]. The physiolo-
gical characteristics of the GA we used in the present
study have been described previously [7,18]; it contained
195 ng CML (/mg protein), 94.9 ± 3.2 Lys modification
(%), 91.6 ± 1.5 Arg modification (%), undetectable fluor-
escent AGE, undetectable IGF-1, and undetectable LPS.
As the concentrations of the other elements were very
low, we considered that the results we obtained were
attributable to the biological effect of GA. In preliminary
experiments, we titrated GA and HA at concentrations
of 0.1, 0.5, 1.0, and 5.0 mg/mL and found that GA at
the lowest concentration, 0.1 mg/mL, inhibited insulin
release to a degree similar to that at higher concentra-
tions. Also, GA has been used at 0.1 mg/mL in two pre-
vious studies [7,18]. Anti-human GA neutralizing
antibody, A717, was added at concentrations of 1.25 and
5.0 μg/mL. The concentrations of other agents used
in the present study were: Tolb 100 μM, glyceraldehyde
10 mM, DHA 10 mM, a-KIC 10 mM, methylpyruvate
10 mM, GLP-1 10 nM, forskolin 10 μM, L-NAME
1 mM, and AG 2 mM.
A portion of the medium was withdrawn from the
incubation and appropriately diluted for the insulin
assay. Insulin was measured using a double-antibody
RIA kit (Eiken Chemical, Tokyo, Japan) [19].
Measurement of intracellular free calcium in islet b-cells
Intracellular free calcium concentration ([Ca
2+]i)w a s
measured using a modification of the method of Gilon
and Henquin [20], and Miura and colleagues [21]. The
overnight-cultured islet cells were loaded with fura-2 for
45-60 min at 37°C in HEPES-buffered medium contain-
ing 120 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2,
1.2 mM MgCl2,2 4m MN a H C O 3, and 10 mM HEPES
(pH 7.4), containing 1 μMf u r a2 - A Ma n d5 . 5m M
glucose. Fura-2-loaded cells were placed in HEPES med-
ium (37°C) containing 3 mM glucose and fixed in a
hand-made chamber (fitted with a peristaltic pump for
perfusion) mounted on the stage of an inverted IX 70
microscope (Olympus, Tokyo, Japan). The loaded cells
were excited at 340 nm and 380 nm, the fluorescence
emitted at 510 nm was captured by an intensified
charge-coupled device camera, and the images were ana-
lyzed using the QuantiCell 700 system (Applied Ima-
ging, Sunderland, UK). The changes in [Ca
2+]i in single
islet cells were calculated from the ratio of the fluores-
cence measured with excitation at 340 nm to that
at 380 nm using the following equation [22]: [Ca
2+]i
(nM) = Kd×(R-Rmin)/(Rmax-R)×b,w h e r eK d is the disso-
ciation constant for fura-2 (224 nM), Rmax and Rmin are
the ratios of the unbound and bound forms of the fura-
2-Ca
2+ complex, respectively, and b is the ratio of the
fluorescence of fura 2 at 380 nm excitation in the
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Rmax and Rmin were estimated using the fluorescence
intensities of fura-2 solution (1 μM) containing 10 mM
CaCl2 and 5 mM EGTA, respectively. The fluorescent
signal generated by binding of [Ca
2+]i to fura-2 is not
influenced by changes in the pH of the bathing solution
over the range 6.0-7.05 [19].
Measurement of cAMP content
cAMP content was measured using a modification of
the method of Nelson et al. [23]. Pancreatic islets were
c u l t u r e do v e r n i g h ta t3 7 ° Ci nR P M Iw i t h5 %F C Sa n d
preincubated for 90 min in HEPES-buffered solution
containing 5.5 mM glucose at 37°C in 5% CO2-95% O2.
T e ni s l e t sw e r et h e np i c k e du pa n di n c u b a t e df o r
30 min at 37°C in KRBH (0.4 mL) in the presence of sti-
mulators. The responses were stopped by addition of
0.2 mL of ice-cold trichloroacetic acid (TCA) to a final
concentration of 6%. The culture tubes were shaken, left
at room temperature for 15 min, and centrifuged at
7800 × g for 10 min. The supernatants were thoroughly
mixed with 1.5 mL of diethyl ether, and the ether phase
containing TCA was discarded. This step was repeated
three times to ensure complete elimination of the TCA.
The extracts and cAMP standards were evaporated,
treated with 400 μL KRBH, and assayed for cAMP using
aR I Ak i tf r o mY a m a s aS h o y u( C h o s h i ,J a p a n )i nw h i c h
the samples and standards are succinylated.
Real-time PCR
Total RNA was isolated from islets using a Total RNA
Isolation kit (Macherey-Nagel, Düren, Germany).
Reverse transcription reactions were performed using a
Rever Tra Ace a-First Strand cDNA Synthesis Kit
(TOYOBO, Osaka, Japan). Briefly, 1 μgo ft o t a lR N A ,
oligo dT-primer, and dNTPs were incubated at 65°C for
5m i n ,t h e n1 0μL of cDNA synthesis mixture was
added and the mixture was incubated at 50°C for
50 min. The reaction was terminated by adding 1 μLo f
RNaseH and incubating the mixture at 37°C for 20 min.
The sequences of the primers were as follows: b-actin:
sense-primer 5’-agccatgtacgtagccatcc-3’,a n t i - s e n s e5 ’-
ctctcagctgtggtggtgaa-3’; iNOS: sense-primer 5’-caccttg-
gagttcacccagt-3’, anti-sense 5’-accactcgtacttgggatgc-3’.
Real-time PCR was performed using an ABI Prism
7700 sequence detector (Applied Biosystems, Warring-
ton, UK). The PCR reaction was carried out in a final
volume of 2 μL cDNA, 12.5 μL 2 × SYBR Green
(Applied Biosystems), 0.5 μLo f2 5n Ms e n s ea n da n t i -
sense primers, and H2Ou pt o2 5μL. The PCR condi-
tions consisted of 40 cycles at 95°C for 30 s and 60°C
for 30 s. Samples were assayed in triplicate. Means and
standard deviations were calculated from the data
obtained. For each sample, at least three assays were
performed. The t value was calculated from the mean of
three different assays. The level of expression was calcu-
lated using the formula: Relative expression (t-value) =
(Copy number of target molecule/Copy number of b-
actin) × 1000 [23].
Western blotting
Anti-iNOS and anti-b-actin antibodies were purchased
from BD Bioscience (Franklin Lakes, NJ). Islet cells pre-
pared as described previously were lysed with 200 μlo f
0.5% (w/v) SDS, and centrifuged at 10000 rpm. The
supernatants were adjusted to contain equal amounts of
protein by dilution, using a BCA Protein Assay Kit
(Pierce, Rockford, IL). Samples (20 μg protein) were run
on 12.5% (w/v) SDS-PAGE with 10% gel and electro-
blotted onto PVDF membranes. The blots were blocked
for 1 h with 5% (w/v) non-fat milk powder and 0.1% (v/
v) Tween 20 in Tris-NaCl, then exposed to the primary
antibody at a 1000-fold dilution overnight at 4°C. After
extensive washing, the blots were incubated with the
secondary horseradish-peroxidase-conjugated antibody
(1:2000) for 2 h at room temperature. Immunoreactive
bands were visualized using an enhanced chemilumines-
cence detection system (Amersham Life Sciences,
Arlington Heights, IL). The levels of protein expression
were estimated quantitatively by densitometric scanning
using a Molecular Imager FX (Bio-Rad Laboratories,
Hercules, CA).
Statistics
Data were expressed as means ± SEM. All statistical
analyses were performed with GraphPad Prism ver 5.0
(La Jolla, CA). Data from the two groups were compared
using two-sided t-test. For Figure 3, repeated measures
analysis of variance was used. Differences at P <0.05
were considered significant.
Results and Discussion
Effect of GA on insulin secretion induced by glucose, high
K
+, and tolbutamide
Insulin secretion in the presence of HA and GA was 20.9
± 3.9 and 21.6 ± 5.5 μU/3 islets/h (P =0 . 9 2 0 )f o rG 3
(Figure 1A), and 154 ± 9.3 and 126.1 ± 7.3 μU/3 islets/h
(P = 0.046) for G15, respectively (Figure 1B). For G3, in
the presence of 1.25 μg/mL anti-human GA neutralizing
antibody, A717, insulin secretion of HA and GA was 19.7
± 4.4 and 23.1 ± 6.0 μU/3 islets/h (P =0 . 6 5 9 ) ,a n di nt h e
presence of 5.0 μg/mL A717, the corresponding values
were 16.8 ± 6.6 and 20.4 ± 5.2 μU/3 islets/h (P = 0.693)
( F i g u r e1 A ) .F o rG 1 5 ,i nt h ep r e s e n c eo f1 . 2 5μg/mL
A717, insulin secretion of HA and GA was 152.7 ± 12.8
and 150.5 ± 6.2 μU/3 islets/h (P = 0.194), and in the pre-
sence of 5.0 μg/mL A717, the corresponding values were
152.7 ± 12.8 and 155.0 ± 12.4 μU/3 islets/h (P =0 . 1 3 9 )
Shiraki et al. Nutrition & Metabolism 2011, 8:20
http://www.nutritionandmetabolism.com/content/8/1/20
Page 3 of 10(Figure 1A). Thus, the anti-human GA neutralizing anti-
body, A717, significantly abrogated the inhibitory effect
of GA on insulin secretion.
Figure 2 shows the effect of GA on the insulin secre-
tion induced by 30 mM K
+ (K30) and Tolb. K30 depo-
larizes the cell membrane of islet b cells without the
need for KATP channel closure. In the presence of K30,
insulin secretion elicited by HA and GA was 116.3 ± 6.1
and 123.6 ± 16.2 μU/3 islets/h for G3 (P = 0.686), and
123.3 ± 15.7 and 124.3 ± 14.7 μU/3 islets/h for G15, (P
= 0.965), respectively. Tolb promotes insulin secretion
by binding to the regulatory sulfonylurea receptor-1
(SUR1) and inhibiting the KATP channel current [25]. In
the presence of Tolb, insulin secretion elicited by HA
and GA was 42.4 ± 3.4 and 53.4 ± 4.7 μU/3 islets/h for
G3 (P = 0.079), and 138.5 ± 6.7 and 123.4 ± 5.4 μU/3
islets/h for G15 (P = 0.536), respectively.
Effect of GA on intracellular Ca
2+ concentration [Ca
2+]i
Figure 3 shows the changes in [Ca
2+]i.[ C a
2+]i was mea-
sured in the presence of G3 during the first 5 min, then
in the presence of G15 for the next 10 min (Figure 3A).
In the presence of HA, [Ca
2+]i reached a maximum level
of 81.7 ± 2.0 nM at 8 min, and remained at higher level
than that in the presence of GA, which was 65.2 ± 0.7
nM at 8 min, and thereafter remained lower than that
in the presence of HA (P = 0.021). To investigate [Ca
2+]
i in the presence of a high extracellular potassium con-
centration or Tolb, [Ca
2+]i was measured in the pre-
sence of HA or GA under the G15 condition for 5 min,
followed by that in the presence of K30 (Figure 3B) or
Tolb (Figure 3C) for 10 min. [Ca
2+]i increased rapidly
after 5 min when islets were cultured in the presence of
G15 and K30 (P = 0.331), or G15 and Tolb (P = 0.236).
Effect of GA on insulin secretion induced by
glyceraldehyde, DHA, a-KIC, and methylpyruvate
Glyceraldehyde and DHA enter the glycolysis pathway
directly and stimulate insulin secretion [26,27]. Insulin
secretion elicited by HA and GA under the G3 condi-
tion was 67.0 ± 3.5 and 53.6 ± 5.3 μU/3 islets/h in the
presence of glyceraldehyde (P = 0.044), and 77.2 ± 5.2
and 58.2 ± 5.4 μU/3 islets/h in the presence of DHA
(P = 0.017), respectively (Figure 4A).
a-KIC enters mitochondrial metabolism through a-
ketoglutamate and increases insulin secretion [28].
Methylpyruvate is a membrane-permeable form of the
mitochondrial fuel pyruvate, and also increases insulin
secretion [29]. Under the G3 condition, insulin secretion
elicited by HA and GA was 108.8 ± 9.4 and 107.9 ± 7.9
μU/3 islets/h in the presence of a-KIC (P = 0.946),
respectively, and 96.4 ± 6.5 and 76.6 ± 6.6 μU/3 islets/h
Figure 1 Effect of GA on insulin secretion. Rat islets were incubated for 24 h at 37°C with 0.1 mg/mL HA (white bar) or GA (black bar) under
G3 (A) or G15 (B) conditions. Labeling of the X-axis represents the dose of anti-human GA neutralizing antibody, A717. Each bar represents the
mean plus SEM of 5 separate experiments, each with n = 4. ss; statistically significant.
Figure 2 Effects of extracellular high potassium and
tolbutamide on insulin secretion. Rat islets were incubated for 24
h at 37°C with 0.1 mg/mL HA (white bar) or GA (black bar), in the
presence of 30 mM K
+ or 100 μM Tolb. Each bar represents the
mean plus SEM of 3 separate experiments, each with n = 4.
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tively. Under the G15 condition, insulin secretion eli-
cited by HA and GA was 121.4 ± 8.0 and 118.3 ± 9.0
μU/3 islets/h in the presence of a-KIC (P = 0.799),
respectively, and 111.2 ± 13.5 and 73.5 ± 8.2 μU/3
islets/h in the presence of methylpyruvate (P =0 . 0 3 1 ) ,
respectively.
To investigate the effect of GA on insulin production,
insulin concentration in b cells was measured. The insu-
lin content in the presence of HA and GA under the G3
condition was 1181.9 ± 72.5 and 1024.6 ± 98.6 μ Unit/3
islets, respectively (P = 0.222), and those under the G15
condition were 1143.6 ± 49.8 and 1040.8 ± 65.8 μ Unit/
3 islets, respectively (P = 0.237).
Inhibition of insulin secretion by GA is cAMP-dependent
Glucose-stimulated insulin secretion is augmented by
the cAMP-dependent amplifying pathway [30]. To
investigate the mechanism of inhibition of insulin secre-
tion by GA further, insulin secretion was tested in the
presence of the incretin, GLP-1, and the activator of
adenylate cyclase, forskolin. Insulin secretion elicited by
HA and GA under the G7 condition was 99.5 ± 12.6
and 61.8 ± 9.6 μU/3 islets/h (P = 0.029) in the presence
of GLP-1, and 185.5 ± 28.3 and 80.1 ± 14.3 μU/3 islets/
h( P = 0.005) in the presence of forskolin (Figure 5A).
Figure 5B shows the cAMP content of the islet b cells.
Under the G7 condition, the cAMP contents elicited by
HA and GA were 24.5 ± 1.1 and 18.1 ± 1.4 pmol/10
islets, respectively (P = 0.003), in the presence of GLP-1,
and 51.4 ± 2.7 and 41.0 ± 2.1 pmol/10 islets, respec-
tively (P = 0.018), in the presence of forskolin.
Inhibition of insulin secretion by GA is not iNOS-mediated
Although the mechanism responsible for the suppres-
sion of insulin release by GA remains unknown, one
Figure 3 Changes in intracellular free calcium concentration ([Ca
2+]i). (A) Effect of GA on ([Ca
2+]i). [Ca
2+]i was measured under the G3
condition during the first 5 min, then under the G15 condition for the next 10 min, in the presence of 0.1 mg/mL HA (thick line) or GA (thin
line). Data represent the mean plus SEM of 2 separate experiments, each with n = 4-10. (B, C) [Ca
2+]i was measured in the presence of HA (thick
line) or GA (thin line) under the G15 condition. Islet cells were incubated for the first 5 min, and then in the presence of 30 mM K
+ (B) or
100 μM Tolb (C) for the next 10 min, in the presence of 0.1 mg/mL HA (solid) or GA (dotted). Data represent the mean plus SEM of 2 separate
experiments, each with n = 4-10. ss; statistically significant.
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inhibits insulin secretion by activating iNOS, resulting in
the inhibition of cytochrome c oxidase and ATP produc-
tion [12]. Insulin secretion was therefore investigated in
the presence of an inhibitor of nitric oxide synthetase,
L-NAME, or a selective inhibitor of iNOS, AG [12].
Insulin secretion in the presence of HA and GA alone
or with L-NAME and AG under the G3 condition was
28.2 ± 3.3, 27.6 ± 4.1, and 25.3 ± 2.2 μU/3 islets/h for
HA (P = 0.921), and 26.3 ± 3.3, 26.4 ± 4.2, and 21.1 ±
2.8 μU/3 islets/h for GA (P = 0.895). The corresponding
results under the G15 condition were 138.1 ± 5.7, 132.0 ±
6.1, and 135.3 ± 8.5 μU/3 islets/h for HA (P = 0.724), and
117.5 ± 3.8, 111.3 ± 4.4, and 107.4 ± 6.0 μU/3 islets/h for
GA (P = 0.847). Figure 6B shows the data for iNOS-
mRNA expression. The t-values of iNOS-mRNA for HA
and GA were 2.2 ± 0.7 and 2.0 ± 1.0 under the G3 condi-
tion (P = 0.877), 2.4 ± 0.8 and 2.1 ± 1.1 under G7 (P<
0.001), and 2.2 ± 0.4 and 2.2 ± 0.6 under G15 (P = 0.822),
respectively. Figure 6C shows the results of Western
blotting. The relative expression of iNOS-protein to b-
actin-protein in the presence of HA and GA was 0.40 and
0.42, respectively (P> 0.05).
The present study has demonstrated for the first time
that glycated albumin (GA) suppresses glucose-induced
insulin secretion from islet b-cells. As shown in Figure
3A, GA significantly decreased [Ca
2+]i, and therefore the
suppression of insulin secretion by GA may be due
mainly to suppression of cytosolic Ca
2+ influx in
response to glucose stimulation.
Am extracellular high potassium concentration (K30)
depolarizes the cell membrane without any need for the
KATP channel current, and activates voltage-sensitive
calcium channels; the calcium influx then stimulates
insulin secretion. As shown in Figure 2, K30 abrogated
the inhibition of insulin secretion by GA, suggesting
that GA inhibits insulin secretion upstream of voltage-
sensitive calcium channels. Tolb binds to SUR1 and
keep the KATP channel closed, thus inhibiting the KATP
channel influx of extracellular Ca
+ and inducing depo-
larization of the cell membrane, consequently inducing
insulin secretion [25]. Tolb abrogated the inhibition of
insulin secretion by GA (Figure 2), suggesting that GA
did not affect the function of the KATP channel. As both
K30 and Tolb increased [Ca
2+]i, (Figure 2B and 2C), the
mechanism responsible for suppression of insulin secre-
tion occurs upstream of the KATP channel.
In the process of insulin secretion by b-cells, glucose
is phosphorylated by glucokinase and forms glucose-6-
phosphate (G6P). The G6P is further metabolized via
glycolysis, to generate ATP. Glyceraldehyde and DHA
are potent insulin secretagogues that enter the glycolytic
pathway directly and produce ATP, resulting in insulin
secretion [26,27]. In the present study, glyceraldehyde
and DHA did not abrogate the inhibition of insulin
secretion by GA (Figure 4A).
Figure 4 Effects of glyceraldehyde, DHA, a-KIC, and methylpyruvate on insulin secretion. (A) Rat islets were incubated for 24 h at 37°C
with 0.1 mg/mL HA (white bar) or GA (black bar), in the presence of 10 mM glyceraldehyde or 10 mM DHA, under the G3 condition. Each bar
represents the mean plus SEM of 3 separate experiments, each with n = 5. (B) Rat islets were incubated for 24 h at 37°C with 0.1 mg/mL HA
(white bar) or GA (black bar), in the presence of 10 mM a-KIC or 10 mM methylpyruvate, under the G3 or G15 condition. Each bar represents
the mean plus SEM of 3 separate experiments, each with n = 5. ss; statistically significant.
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late mitochondrial metabolism and induce insulin secre-
tion. a-KIC is a transamination partner, which enters
mitochondrial metabolism through a-ketoglutamate and
induces mitochondrial NADPH, thus increasing insulin
secretion [28]. As shown in Figure 4B, KIC restored
insulin secretion from rat b-cells, and methylpyruvate
[29] did not abrogate the inhibitory effect of GA.
Although the discrepancy between the effects of a-KIC
and methylpyruvate is not fully understood, a previous
Figure 5 Effects of GLP-1 and forskolin on insulin secretion. (A) Rat islets were incubated for 24 h at 37°C with 0.1 mg/mL HA (white bar) or
GA (black bar), in the presence of 10 nM GLP-1 or 10 μM forskolin, under the G7 condition. Each bar represents the mean plus SEM of 3
separate experiments, each with n = 5. (B) Dissociated islet cells were cultured overnight at 37°C in DMEM with 5% FCS. Islet cells were
preincubated for 30 min at 37°C in KRBH (0.4 mL) in the presence of GLP-1 or forskolin, under the G7 condition. ss; statistically significant.
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chondrial metabolism but also stimulates the KATP
channel directly [30]. Pyruvate is an end-product of
aerobic glycolysis and transported to mitochondria after
oxidization to form acetyl coenzyme A (CoA), then
entering the tricarboxylic acid (TCA) cycle. In b-cells,
the supply of nicotinamide adenine dinucleotide (NAD
+)
from the oxidization of pyruvate is insufficient. Eto et al.
reported that the NADH shuttle, including the glycerol-
3-phosphate shuttle and the malate-aspartate shuttle,
utilizes mitochondrial electrons to reoxidize NADH,
thus playing an important role in the production of
ATP in b-cell mitochondria [31]. Because, in the present
study, addition of methylpyruvate did not restore insulin
secretion, GA appears to also impair NADH shuttle.
GLP-1 stimulates insulin secretion by increasing
cAMP [34]. Forskolin is a potent activator of adenylate
cyclase [35]. Activation of adenylate cyclase/cAMP leads
to the activation of protein kinase A, which in turn
increases Ca
2+ influx to b-cells [36]. Because GLP-1 and
forskolin did not restore insulin secretion and the
cAMP content in b-cells, it was suggested that the path-
way for amplification of insulin secretion by adenylate
cyclase/cAMP was also impaired by GA treatment. We
also investigated the effect of acetylcholine (ACh) on the
suppression of insulin secretion by GA, and found that
ACh did not elicit recovery of insulin secretion (data
not shown). ACh binds to the muscarinic receptor of b-
cells and activates phospholipase C-b (PLC), then stimu-
lates release of Ca
2+ from the endoplasmic reticulum
[37].
Zhao et al. reported that glucose-derived AGE inhibits
insulin secretion by activating iNOS, resulting in inhibi-
tion of cytochrome c oxidase and ATP production [12].
Our results were contradictory to theirs; GA did not
increase the expression of iNOS-mRNA (Figure 6A),
and the inhibitor of nitric oxidase synthetase, L-NAME,
and AG, did not restore insulin secretion. In Zhao’s
study, L-NAME and AG abrogated the inhibition of
insulin secretion by glucose-derived AGE, although
insulin secretion did not fully return to the normal level.
As mentioned earlier, AGEs bind to RAGE, and
Figure 6 Inhibition of insulin secretion by GA is not iNOS-mediated.( A )R a ti s l e t sw e r ei n c u b a t e df o r2 4ha t3 7 ° Cw i t h0 . 1m g / m LH A
(white bar) or GA (black bar), in the presence of the inhibitor of nitric oxide synthetase, L-NAME, at 1 mM, or the selective inhibitor of iNOS, AG,
at 2 mM, under the G3 or G15 condition. Each bar represents the mean plus SEM of 3 separate experiments, each with n = 5. (B) Real-time PCR
was performed with cDNA from RNA that had been isolated from HA- or GA-treated rat islet cells. t-value is the relative amount of iNOS-mRNA
to b-actin-mRNA. (C) Rat islets were incubated for 24 h at 37°C with 0.1 mg/mL HA or GA, and the proteins isolated from islet cells were stained
with anti-b-actin or anti-iNOS antibody.
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Page 8 of 10transduce signals to downstream pathaways, including
mitogen-activated protein kinases, the Janus Kinase-sig-
nal transducer and activation of transcription pathway,
and phosphoinositol 3 kinase [38]. These signals result
in activation of nuclear factor B( N F B), and increase
the expression of iNOS, C-reactive protein (CRP), trans-
forming growth factor-b, and other molecules. Although
RAGE interacts with multiple ligands, it remains unclear
whether GA binds RAGE or not. GA is not an AGE,
and as the mechanism involved may be different, we
suggest that induction of iNOS and impairment of mito-
chondrial cytochrome c does not play a major role in
the inhibition of insulin secretion by GA.
Conclusion
GA suppresses glucose-induced insulin secretion from
rat pancreatic b cells through impairment of intracellu-
lar glucose metabolism.
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